Related references
Note: Only part of the references are listed.New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation
Roger Kist et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2017)
Computer Aided Drug Design: Success and Limitations
Mohammad Hassan Baig et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays
Ling Wang et al.
SCIENTIFIC REPORTS (2016)
A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches
Mohd Rehan
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2015)
Impact of the subtle differences in MMP-12 structure on Glide-based molecular docking for pose prediction of inhibitors
Huan Zhang et al.
JOURNAL OF MOLECULAR STRUCTURE (2014)
Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches
Mohammad S. Jamal et al.
PLOS ONE (2014)
Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
Mohd Rehan et al.
PLOS ONE (2014)
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Jiri Polivka et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
MoMA-LigPath: a web server to simulate protein-ligand unbinding
Didier Devaurs et al.
NUCLEIC ACIDS RESEARCH (2013)
Design, Synthesis, Evaluation and Thermodynamics of 1-Substituted Pyridylimidazo[1,5-a]Pyridine Derivatives as Cysteine Protease Inhibitors
Mohd Sajid Khan et al.
PLOS ONE (2013)
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
Mamta Gupta et al.
BLOOD (2012)
mTOR inhibitors in cancer therapy
Yekaterina Y. Zaytseva et al.
CANCER LETTERS (2012)
The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK
Natalie B. Vinh et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2012)
Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors
Karunakar Tanneeru et al.
JOURNAL OF MOLECULAR MODELING (2012)
Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2011)
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
S. J. Shuttleworth et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Yan-Jie Zhang et al.
DRUG DISCOVERY TODAY (2011)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
Nathalie Carayol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A Spectroscopic Investigation into the Interactions of 3′-O-Carboxy Esters of Thymidine with Bovine Serum Albumin
Kalyan Sundar Ghosh et al.
BIOPOLYMERS (2009)
Not all substrates are treated equally Implications for mTOR, rapamycin-resistance and cancer therapy
Andrew Y. Choo et al.
CELL CYCLE (2009)
PI3K and mTOR inhibitors - a new generation of targeted anticancer agents
Saskia Brachmann et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
mTOR inhibitors in the treatment of cancer
Angelica Fasolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Chi Kwan Tsang et al.
DRUG DISCOVERY TODAY (2007)
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
M. N. Corradetti et al.
ONCOGENE (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
A path planning approach for computing large-amplitude motions of flexible molecules
J Cortés et al.
BIOINFORMATICS (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Comparative evaluation of 11 scoring functions for molecular docking
RX Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Further development and validation of empirical scoring functions for structure-based binding affinity prediction
RX Wang et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2002)
DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases
TJA Ewing et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2001)
Share Paper
